.August 9, 2024 03:25:01 AM

Emergent BioSolutions Inc. (NYSE: EBS) reported a revenue of $254.7 million, exceeding expectations, but faced a net loss of $283.1 million. The company saw a decline in revenues from NARCAN® Nasal Spray and Smallpox MCM products, but an increase in Anthrax MCM products and Bioservices revenues. Emergent has taken strategic steps to stabilize its financial position, including securing U.S. government contracts, selling assets, and resolving contract disputes. The company remains committed to its mission of public health preparedness despite financial challenges.